Limited coverage criteria – rabeprazole

Last updated on March 21, 2025

 

Return to Special Authority drug list 

Generic name

rabeprazole                                                                                                  

Strength & form

10 mg/20 mg tablet

Special Authority criteria

Approval period

For gastroesophageal reflux disease (GERD), reflux esophagitis, duodenal ulcer, or gastric ulcer

Indefinite

For Barrett's esophagus, Zollinger-Ellison syndrome, connective tissue disease, e.g., lupus, scleroderma, CREST1

Indefinite

For eradication of Helicobacter pylori as part of triple therapy

Maximum 14 days

Practitioner exemptions

Practitioners in the following specialty are not required to submit a Special Authority request for coverage:

  • Gastroenterologists

Special notes

  • 1CREST is an acronym for the five main features of the limited form of scleroderma: calcinosis, Raynaud’s disease, esophageal dysmotility, sclerodactyly, and telangiectasia

Special Authority request form(s)